RAG AI answers Taiwan cancer patients to ease clinician load
The system pulls from medical literature so anxious users get sourced responses between appointments.
Taiwanese hospitals are exploring artificial intelligence and remote patient support as rising cancer-related enquiries add to clinician workloads and staff burnout.
Linda Wu, product manager at oncogen AI, said hospitals are seeking ways to answer routine patient questions outside consultations without placing further pressure on healthcare professionals.
“Taiwan healthcare is facing huge demand and professional burnout because clinicians need to answer cancer patients and provide professional responses,” Wu said in an interview during the Medical Taiwan 2026. “A lot of hospitals are eager to have remote patient management and AI automation management.”
Oncogen AI is focusing on retrieval-augmented generation, or RAG AI, which draws information from medical literature before producing responses.
“We are focusing more on RAG AI because we want to help patients relieve their anxiety,” Wu said. “They can always ask AI their questions, and we can retrieve data and articles to provide professional answers.”
The approach could help hospitals reduce the volume of repetitive enquiries handled by doctors and nurses, whilst giving patients another source of information during treatment. It is intended to support communication rather than replace diagnosis, clinical judgement or direct medical advice.
Wu expects Taiwan’s healthcare sector to rely more heavily on remote services and AI-assisted patient management over the next three years.
“I think Taiwan will shift to a decentralised, AI-driven system for patients,” she said. “They would like to create more remote patient management and use AI to support healthcare.”
For hospitals, the main test will be whether these systems can consistently retrieve reliable sources, explain their answers clearly and direct patients to medical professionals when questions require clinical assessment.
Commentary
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings
Beyond symptom control: Redefining IMID care in Malaysia
How decentralised clinical trials can unlock Asia's research potential